Search
GH Research PLC
GHRSAdd to Watchlist
27.010USD
+0.590+2.23%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.68BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.23%
5 Days
-4.29%
1 Month
+16.17%
6 Months
+104.00%
Year to Date
+112.68%
1 Year
+81.09%
Key Figures
26.420Open
27.300High
168.34KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.27%Turnover Ratio
26.420Prev. Close
25.565Low
3.62MTurnover
LossP/E Static
6.36P/B
0.00%Div Yield TTM
-18.94%ROA
24.66052wk High
1.32Volume Ratio
-38.96MNet Profit
62.05MShares
-0.9100EPS TTM
1.29Beta
-19.67%ROE
10.96052wk Low
6.57%Amplitude
--Gross Margin
1.68BMarket Cap
2.93Reward/Risk
4.65%Risk Rate
TradingKey Stock Score
No stock score available due to insufficient data.
GH Research PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GH Research PLC Info
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Ticker SymbolGHRS
CompanyGH Research PLC
CEOValcheva (Velichka)
Website
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of GH Research PLC (GHRS)?
The current price of GH Research PLC (GHRS) is 27.01.
What is the symbol of GH Research PLC?
The ticker symbol of GH Research PLC is GHRS.
What is the 52-week high of GH Research PLC?
The 52-week high of GH Research PLC is 24.66.
What is the 52-week low of GH Research PLC?
The 52-week low of GH Research PLC is 10.96.
What is the market capitalization of GH Research PLC?
The market capitalization of GH Research PLC is 1.68B.
Is GH Research PLC (GHRS) currently rated as Buy, Hold, or Sell?
According to analysts, GH Research PLC (GHRS) has an overall rating of Buy, with a price target of 38.56.
What is the Earnings Per Share (EPS TTM) of GH Research PLC (GHRS)?
The Earnings Per Share (EPS TTM) of GH Research PLC (GHRS) is -0.79.